多西紫杉醇联合卡培他滨新辅助化疗13例局部晚期乳腺癌的观察

目的探讨多西紫杉醇联合卡培他滨新辅助化疗方案治疗局部晚期乳腺癌的疗效及安全性。方法 13例局部晚期乳腺癌初治患者,卡培他滨药2500 mg/(m2?d),分早晚2次,餐后30 min口服。连续服用2周,休息1周为1个周期。多西紫杉醇75 mg/m2,静脉输注1 h滴完。21 d为1个周期,2周期后评价疗效。结果 13例局部晚期乳腺癌中治疗后完全缓解4例,部分缓解6例,稳定2例,进展1例,有效率76.92%(10/13),主要不良反应为白细胞减少,发生率为82.33%,其中Ⅲ度占29.61%,没有发现有Ⅳ度。结论多西紫杉醇联合卡培他滨新辅助化疗方案治疗局部晚期乳腺癌疗效确切,不良反应可耐受。

Clinical Observation of Neoadjuvant Chemotherapy with Docetaxel plus Capecitabine in Treatment of Patients with Locally Advanced Breast Cancer 13 Cases

Objective To observe the curative effect and security of Neoadjuvant chemotherapy with docetaxel plus capecitabine in treatment of patients withlocally advanced breast cancer. Methods Twenty six patients were treated with oral capecitabine, 2500 mg/m^2/d, on days 1-14 every 21 days, twice daily, plus docetaxel 75 mg/m^2 intravenous drip on first day every 21 days, and the clinical response was assessed after three cycles. Results Among 13 cases, CR 4 cases, PR 6 cases, Steady 2 cases, develop 1 case, efficient rate 76.92%（10/13）.The main poisonous side effect are reduced the leucocyte, the incidence is 82.33%, among them Ⅲ degree accounts for 29.61%, no Ⅳ degree. Conclusion Neoadjuvant chemotherapy with docetaxel plus capecitabine in treatment of patients with locally advanced breast cancer schemeis effective, The poisonous side reaction can be tolerable.